ACT Brief: AI Freeing Experts for Decision Making, Community Trust in Trial Engagement, and Lupus Treatment Breakthroughs

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part two of his video interview, Abraham Gutman described how AI can assume rote reasoning tasks like PHI redaction and document quality assurance. Offloading that work gives human experts the clarity and capacity to focus on genuine decision making rather than routine validation tasks.
• In a new Q&A building off his earlier video interview, Del Smith, CEO and co-founder of Acclinate, discussed how structural and relational barriers continue limiting underrepresented community participation in trials. Smith emphasized that sustained, authentic engagement—distinct from transactional recruitment—builds the trust necessary for lasting research impact and measurably improves trial outcomes and diversity metrics.
• In another new Q&A from Pharmaceutical Executive, Albert Roy, CEO and president of the Lupus Research Alliance, discussed recent treatment breakthroughs that are reshaping the patient experience. Newer therapies with potential to reset the immune system are replacing symptom-focused approaches dependent on damaging steroids, signaling a meaningful shift in standard of care.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.